newsfilter
← Latest News
Business Wire·

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

- 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions;